Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific personnel transaction rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported. The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan, resulting in an increase in the notional allocation of American Depositary Shares (ADSs).
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R (1)(c).
Key Facts for Investor Verification
- Transaction Date: The notional allocation increase occurred on March 30, 2012.
- Price: The transaction price was $44.91 per ADS.
- Parties Involved: The transaction involved Director Dr. M. M. Slaoui and Connected Person Dr. K. Slaoui.
- Volume: The increase consisted of 5 ADSs.
- Context: This was a revaluation of a notional investment within a retirement plan, not a direct market purchase or sale by the individuals.